Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease: A systematic review

International Journal of Technology Assessment in Health Care

Volumn 18, Issue 3, 2002, Pages 497-507

  Clegg, Andrew ^a   Bryant, Jackie ^a   Nicholson, Tricia ^a   McIntyre, Linda ^a   De Broe, Sofie ^a   Gerard, Karen ^a   Waugh, Norman ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Review

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ALZHEIMER DISEASE; BEHAVIOR; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; ECONOMIC EVALUATION; FUNCTIONAL ASSESSMENT; HEALTH; HUMAN; MOOD; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

AGED; ALZHEIMER DISEASE; CARBAMATES; CHOLINESTERASE INHIBITORS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; GALANTAMINE; HUMANS; INDANS; PHENYLCARBAMATES; PIPERIDINES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0036622723     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S026646230200034X     Document Type: Review

References (51)

1. Agid Y, Dubois B, Anand R, Gharabawi G. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr Ther Res Clin Exp. 1998;59:837-845.
2. Alzheimer's Society Web site. Available at: http://146.101.3.157/about/statistics.html. Accessed in 2000.
3. Benbow S, Jones R, Jolley D. Prescribing: short rations. Health Serv J. 1999;109:26-27.
4. Bentham P, Gray R, Raftery J. More reliable assessments of donepezil efficacy urgently needed. Progress in Neurology and Psychiatry. 1998;2:13-14.
5. Bero LA, Rennie D. Influences on the quality of published drug studies. Int J Technol Assess Health Care. 2000;12:209-237.
6. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. The Cochrane Library. Oxford: Update Software; 2001.
7. Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease. The Cochrane Library. Oxford: Update Software; 2001.
8. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342.
9. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease: Results from a multinational trial. Dementia Geriatr Cogn Disord. 1999;10:237-244.
10. Clegg A, Bryant J, Nicholson T, et al. Clinical and cost effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: A rapid and systematic review. Health Technol Assess. 2001;5:1-137.
11. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998;1:55-65.
12. Donepezil for Alzheimer's disease? Drug Ther Bull. 1997;35:75-76.
13. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275-283.
14. Fenn P, Gray A. Estimating long term cost savings from treatment of Alzheimer's disease: A modelling approach. Pharmacoeconomics. 1999;16:165-174.
15. Flicker L. Acetycholinesterase inhibitors for Alzheimer's disease. BMJ. 2000;318:633-638.
16. Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon registered). Eur J Neurol. 1999;6:423-429.
17. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: A randomized crossover study. Arch Neurol. 2000;57:94-99.
18. Greenhalgh T. Advertisements for donepezil. BMJ. 1997;315:1623.
19. Hauber AB, Gnanasakthy A, Mauskopf JA. Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine. Clin Ther. 2000;22:439-451.
20. Hauber AB, Gnanasakthy A, Snyder EH, et al. Potential savings in the cost of caring for Alzheimer's disease: Treatment with rivastigmine. Pharmacoeconomics. 2000;17:351-360.
21. Henderson S. Epidemiology of dementia. Ann Med Interne. 1998;149:181-186.
22. Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000;11:299-313.
23. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomised clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1-12.
24. Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: A Markov model. Clin Ther. 1999;21:1230-1240.
25. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282:1054-1060.
26. Melzer D. Personal paper. New drug treatment for Alzheimer's disease: Lessons for healthcare policy. BMJ. 1998;316:762-764.
27. National Institute for Clinical Excellence Web site. Available at: http://www.nice.org.uk/Article.asp?a = 14487. Accessed in 2001.
28. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology. 1999;52:1138-1145.
29. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD guidelines for those carrying out or commissioning reviews. London: NHS; 1999. CRD report 4.
30. O'Brien BJ, Goeree R, Hux M, et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc. 1999;47:570-578.
31. O'Brien BJ, Heyland D, Richardson WS, Levine M, Drummond MF. Users' guides to the medical literature, XIII: How to use an article on economic analysis of clinical practice, B: What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA. 1997;277:1802-1806.
32. Olin J, Schneider L. Galantamine for Alzheimer's disease. The Cochrane Library. Oxford: Update Software; 2001.
33. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomised, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261-2268.
34. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998;158:1021-1031.
35. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebocontrolled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998;50:136-145.
36. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol. 1998;8:67-75.
37. Rogers SL, Friedhoff LT, Apter JT, et al. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293-303.
38. Rosler M, Anand R, Cicin SA, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ. 1999;318:633-640.
39. Schneider LS. New therapeutic approaches to Alzheimer's disease. J Clin Psychiatry. 1996;57:30-36.
40. Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ. 1996;5:1-11.
41. Sonnenberg FA, Roberts MS, Tsevat J, et al. Toward a peer review process for medical decision analysis models. Med Care. 1994;32:JS52-JS64.
42. Sramek JJ, Anand R, Wardle TS, et al. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci. 1996;58:1201-1207.
43. Sramek JJ, Cutler NR. Recent developments in the drug treatment of Alzheimer's disease. Drugs Aging. 1999;14:359-373.
44. Stein K. Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT). Bristol: NHS; 1997. NHS Executive South and West. Development and Evaluation Committee Report.
45. Stein K. Rivastigmine (Exelon) in the treatment of senile dementia of the Alzheimer type (SDAT). Bristol: NHS; 1998. NHS Executive South and West. Development and Evaluation Committee Report.
46. Stewart A. Pharmacotherapy in the treatment of people with Alzheimer's disease: A Markov-cycle evaluation of donepezil. PSSRU; 1997. Discussion paper 1342/2.
47. Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer's disease: A Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriatr Psychiatry. 1998;13:445-453.
48. Tariot P, Solomon PR, Morris J, et al. A 5-month, randomised, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269-2276.
49. Wilcock G, Wilkinson D. Galanthamine hydrobromide: Interim results of a group comparative, placebo controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer type. In Iqbal K, Winblad B, Nishimura T, Takeda M, Wiesniewski HM, eds. Alzheimer's disease: Biology. diagnosis and therapeutics. New York: Wiley & Sons Inc; 1997:661-664.
50. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. BMJ. 2000;321:1445-1449.
51. Wolfson C, Moride Y, Perrault A, et al. Drug treatments for Alzheimer's disease, I: A comparative analysis of clinical trials. Ottawa: CCOHTA; 2000.